Concerns and Legal Actions Surrounding GLP-1 Drugs
Shelley and Todd Engel’s life took a sudden turn when Todd, after operating heavy machinery for decades, experienced vision loss due to optic neuropathy. His doctor had prescribed Ozempic for diabetes in early 2023. On New Year’s Eve, Todd found his vision in the right eye obscured and later lost sight in the left eye. Their doctor initially did not connect Ozempic to this condition, known as NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy), an inoperable issue stemming from tiny strokes disrupting blood flow to the eye.
Subsequent research published seven months later in JAMA Ophthalmology indicated a higher incidence of NAION among diabetic Ozempic users. Unaware of this connection, Engel continued his medication until both eyes suffered vision loss. Engel has launched legal action, accusing Novo Nordisk, the manufacturer, of failing to provide adequate warnings about NAION risks. This case is part of larger legal proceedings targeting GLP-1 drugs, which are linked to serious health complications.
Novo Nordisk maintains that the allegations lack foundation, citing research refuting the causal link between GLP-1 drugs and NAION. They contend that the correlation found in studies does not imply causation, a sentiment echoed by the American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society. These groups acknowledge a potential link but assert more research is necessary. At present, they do not advise patients to cease using GLP-1 medications.
The Food and Drug Administration (FDA) oversees a database tracking adverse events related to pharmaceuticals. Although the reports are typically voluntary, the agency uses this information as a preliminary step to initiate further evaluations. According to NPR, over 1,000 reports of optic neuropathy linked to GLP-1s have been documented since 2024.
Novo Nordisk reports that serious conditions like NAION are extremely rare in clinical trials. They continue to provide data to the FDA, which is conducting its own investigation on NAION. The FDA has not mandated updates to warning labels, awaiting results from their analysis.
“These warnings would have made a difference in the lives of real people,” argues Jonathan Orent, a lead attorney in multi-district litigation concerning GLP-1 drugs. He stresses the importance of updating warnings even if adverse effects are infrequent.
Orent represents numerous plaintiffs, including 247 with NAION and over 4,000 with severe digestive conditions. Eli Lilly, another drug manufacturer, insists they will robustly defend against these claims.
The complexities of obesity and diabetes complicate identifying issues directly caused by GLP-1 drugs. Dr. Mohammed Ali at Emory University did not report complications because he could not definitively attribute them to the drugs, despite timing coincidences. This uncertainty often results in underreporting.
Online sales of GLP-1s, heavily marketed through platforms like Instagram, further complicate accountability due to insufficient patient monitoring. Robert Miller from West Texas Poison Control Center notes an increase in inquiries related to GLP-1 side effects. He questions whether patients have adequate channels to report these effects.
The Engels’ legal battle highlights ongoing safety and regulatory debates over GLP-1 drugs. Shelley Engel advocates for clearer warnings, believing they might have prevented her husband’s eyesight loss. The case underscores the need for diligent monitoring and clearer communication of potential drug side effects.